Reticulocalbin-1 activators consist of a diverse set of chemicals that predominantly center around the modulation of endoplasmic reticulum functions. These chemicals span a wide spectrum of actions, from inducing ER stress, altering calcium dynamics, to disrupting protein processing or degradation in the ER. Given RCN1's localization in the ER and its role in calcium binding, chemicals affecting these processes can play a role in its modulation. For instance, agents like Cyclopiazonic Acid, which affect the SERCA pump and subsequently deplete ER calcium, might impact RCN1 as the ER attempts to adapt to the altered calcium environment. Furthermore, chemicals like Tunicamycin and Brefeldin A, which interfere with protein processing and trafficking between the ER and Golgi, provide another angle of influence on RCN1. This is especially relevant given the ER's crucial role in ensuring proteins are correctly folded and post-translationally modified.
Other chemicals in this class, such as Dantrolene and 2-APB, pivot on the modulation of calcium release mechanisms from the ER. Given RCN1's calcium-binding role, any shift in ER calcium dynamics can position RCN1 in a pivotal spot for cellular adaptation. Another layer of modulation is brought in by MG-132, which, by affecting protein degradation routes, can lead to protein accumulation in the ER. The subsequent ER stress can trigger a cascade of events, including the unfolded protein response, where RCN1 might see modulated activity or expression. Together, these chemicals underscore the vast interconnectivity and importance of the ER in cellular function, and by extension, highlight the pathways and processes through which RCN1 can be influenced.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene modulates ryanodine receptors, reducing calcium release from ER. This might lead to changes in ER calcium balance, potentially affecting RCN1 function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER-Golgi trafficking. The disruption can lead to altered protein processing in the ER, potentially influencing RCN1 activity in the process. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
2-APB acts on IP3 receptors, altering calcium release from the ER. This action can impact ER calcium homeostasis, potentially modulating RCN1. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, an L-type calcium channel blocker, can alter calcium dynamics. Indirectly, this may impact the calcium-binding activity of RCN1 in the ER. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
An inhibitor of the SERCA pump, it depletes ER calcium stores. The resultant calcium imbalance in the ER might affect the function or levels of RCN1. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $510.00 | 14 | |
As an IP3 receptor antagonist, Xestospongin C affects calcium release from ER, which could indirectly modulate calcium-binding proteins like RCN1. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol induces ER stress by impacting protein folding. The resultant UPR can potentially modulate RCN1 expression or function. | ||||||